Nephrodite Inc.
Nephrodite is developing a combined implantable and wearable device that represents a change in the way end-stage renal disease treatment is delivered. The Holly device will remove the need for frequent visits to a dialysis center and resolve the lack of mobility that accompanies traditional dialysis treatment. The inspiration for this innovation was the heart Left Ventricular Assist Device (LVAD), which has been proven to function in situ for extended periods, first as a bridge to transplant and later as a stand-alone device.